

Figure 2 Illustration of CAVI measurement.

assay; high density lipoprotein cholesterol (HDL-C) by modified enzymatic method; uric acid by uricase peroxides method, glucose by hexokinase glucose-6-phosphate dehydrogenase assay, glyco-hemoglobin A1c (HbA1c) by latex agglutination, and white blood cells (WBC) by direct current detection method. To identify subjects with ischemic changes, outputs from electrocardiogram were classified by Minnesota code [16] which has been internationally and uniformly used in the epidemiology setting. Retinal photographs of the right eye were taken by non-mydriatic retinal camera (Canon Co., Tokyo, Japan) to identify subjects with abnormal changes in retinal arteries by using Scheie's classification method [17].

The criteria to select subjects for the CVD risk-free group and for the CVD high-risk group were based on the guidelines established by Japan Atherosclerosis Society and Japan Society of Hypertension [18-21]. The CVD risk-free persons were defined as those meeting the following clinical criteria at the time of screening:

- blood pressure: systolic blood pressure (SBP) \leq 139 mmHg and diastolic blood pressure (DBP) \leq 89 mmHg;

- serum lipids: TC \leq 219 mg/dL, HDL-C = 40-99 mg/dL and TG \leq 149 mg/dL;
- serum glucose: glucose \leq 109 mg/dL and HbA1c \leq 5.8%;
- renal function: creatinine: male \leq 1.10 mg/dL, female \leq 0.80 mg/dL and uric-acid \leq 7.0 mg/dL for both genders;
- white blood cells: $3.2-8.5 \times 10^3/\mu\text{L}$;
- electrocardiogram: excluding persons with 1-1-1 to 1-3-6, 3-1 to 3-3, 4-1 to 4-4, 5-1 to 5-5, and 9-2; and
- retinal artery changes: no arteriolar sclerotic change and no hypertensive change.

The CVD high-risk persons were defined as those who fall in one or more following groups of clinical abnormalities at the time of screening:

- borderline hypertension group: SBP:140-159 mmHg, and/or DBP:90-99 mmHg;
- hypertension group: SBP \geq 160 mmHg, and/or DBP \geq 100 mmHg;
- abnormal lipid metabolism group: TC \geq 240 mg/dL, TG \geq 250 mg/dL, and/or HDL-C \leq 34 mg/dL;

- borderline high-glucose group: serum glucose 110-125 mg/dL and/or HbA1c 5.9-6.1%;
- hyperglycemia group: serum glucose \geq 126 mg/dL and/or HbA1c \geq 6.2%;
- ischemic change group: 1-1-1 to 1-1-3 (abnormal Q wave), and/or 4-1 to 4-3 (ischemic change); and
- arteriolar sclerotic change group: sclerotic change \geq II in Scheie's method.

Statistics Methods

In addition to the use of descriptive statistics, Student's t-test using two independent samples was applied to a comparison of means between two groups and $p < 0.05$ was considered statistically significant. Statistical Packages for Social Sciences version 16 was used for data analysis.

Results

As shown in Table 1, there were 2,239 men and 3,730 women who were free from clinical CVD abnormalities. Table 2 represents age-specific means and standard deviations of the baseline CAVI scores from the CVD risk-free group by age and gender. Age-specific average CAVI scores became higher in both genders as their age advanced and 0.22-0.66 of increment was added to the average CAVI score as the age increased to every 10 years.

Figure 3 shows a comparison of age-specific average CAVI scores between genders. It is observed that average CAVI scores at each age-interval were significantly greater for men than for women with a borderline significance for 70-74 years of age ($p = 0.071$), and that men's CAVI scores were about 5 years ahead of women's between 30 and 60 years of age and even 10 years ahead of women's after 60 years of age.

Tables 3 and 4 show a comparison of average CAVI scores between the CVD risk-free group and each CVD high-risk group by age among men and among women, respectively. There were not enough cases of all CVD

high-risk groups under 30 years of age for comparisons and of some CVD high-risk groups 30-39 years of age. Most average CAVI scores from each of the CVD high-risk groups were significantly higher than those from the CVD risk-free groups with one exception: the average CAVI score (6.95) of the hypercholesterolemia and hypertriglyceridemia group for men 30-39 years of age was significantly smaller than that (7.12) of the CVD risk-free group for the same gender and age-bracket ($p = 0.021$). On one hand, age-specific average CAVI scores of the hypertension group were significantly greater than those of the CVD risk-free group after 30 years of age among men but after 40 years of age among women. On the other hand, age-specific average CAVI scores of the hypercholesterolemia and hypertriglyceridemia group, the hyperglycemia group, the ischemic changes group, and the retinal artery changes group were significantly greater for both men and women after 40 years of age compared to those of the CVD risk-free group with exceptions of non-significance in the hypercholesterolemia and hypertriglyceridemia group of men 70-74 years of age ($p = 0.106$), in the hyperglycemia group of women 40-49 years of age ($p = 0.093$), and in the ischemic changes group and the retinal artery changes group of women 70-74 years of age ($p = 0.052$ and $p = 0.071$, respectively).

Figures 4 and 5 show differences in average CAVI scores by age between the CVD risk-free group and all CVD high-risk groups combined for men and for women, respectively. After 40 years of age, the difference in age-specific average CAVI scores became statistically significant between the two groups, with borderline significance in men 70-74 years of age ($p = 0.054$), and also became wider as age advanced both for men and for women.

Discussion

As shown in Table 2, we have established the baseline CAVI scores based on 5,969 CVD risk-free persons selected out of 32,627 persons 20-74 years of age. It is shown that there exists a linear association between CAVI scores and age in both genders confirming that aging is an independent risk factor of atherosclerosis and cardiovascular disease as described in western [22,23] and Japanese studies [24]. Table 2 and Figure 3 show a biological aging of major arteries among CVD risk-free persons. We found that age-specific average CAVI scores among men were significantly greater than among women. Such a finding is consistent with the fact that men have a higher risk for coronary heart disease (of which one major risk factor is arteriosclerosis) than women [1,2]. Based on these findings, we need to evaluate an individual's CAVI scores according to his/her age and gender when we conduct screening.

Table 2 Comparison of average cardio-ankle vascular index (CAVI) scores of CVD risk-free subjects by age and gender

Age	Males		Females		t-value	p-value
	Mean	SD	Mean	SD		
20-29	6.69	0.70	6.57	0.66	2.89	$p = 0.005$
30-39	7.12	0.68	6.79	0.63	5.23	$p < 0.001$
40-49	7.59	0.70	7.29	0.66	7.82	$p < 0.001$
50-59	8.07	0.76	7.82	0.70	4.97	$p < 0.001$
60-69	8.73	0.81	8.26	0.72	4.95	$p < 0.001$
70-74	9.35	1.00	8.71	0.75	1.88	$p = 0.071$

Note: SD indicates standard deviation.




Figure 3 Differences in average CAVI scores by age between males (blue line) and females (green line) among CVD risk-free individuals based on results shown in Table 2 (Vertical bars indicate standard deviation).

As established by Framingham studies and others [25-27], hypertension is a risk factor of cardiovascular disease. Hypertension is also significantly associated with PWV [9,10,28]. High PWV values are found to be an independent predictive factor of cardiovascular disease [29]. Since our results indicate that age-specific average CAVI scores in the hypertension group were significantly higher than those from the CVD risk-free group (Tables 3, 4), it is implied that hypertension is a risk factor of arteriosclerosis.

The association between serum lipid levels and atherosclerotic disease, namely coronary heart disease, has been established through the findings from several epidemiological studies such as the Seven Countries Study [30], the Multiple Risk Factor Intervention Trial Study [31], and Klag et al's follow-up study [32]. Namekata et al. reported that abnormally high PWV was significantly associated with 4.5 or greater value of the ratio of total cholesterol to high density lipoprotein (HDL) cholesterol implying that abnormal lipid imbalance is a risk factor of arterial stiffness and arteriosclerosis [9]. Our results support such an association by showing that age-specific average CAVI scores among persons with

hypercholesterolemia and hypertriglyceridemia of ages 40 and over were significantly greater than those among CVD risk-free persons for the same age-specific groups (Tables 3, 4).

Diabetes mellitus is proven to be a risk factor for cardiovascular disease [33,34]. It is reported that CVD risk among diabetics was 2-6 times higher than among non-diabetics and PWV values were associated with fasting glucose levels among diabetics [35,36]. An odds ratio for having abnormally high PWV among diabetics is also reported to be 3.66 ($p < 0.001$) as compared to non-diabetics [9]. Our results are consistent with these findings by showing significantly higher average age-specific CAVI scores among persons with hyperglycemia after 40 years of age than those among CVD risk-free persons (Tables 3, 4).

Ischemic changes in ECG and arteriolar changes in retina are considered as surrogate markers of arterial stiffness and arteriosclerosis in the coronary arteries and retinal arteries, respectively. It is also shown that atherosclerotic lesions in the aorta proceeds onset of CVD [37-39], as an increase in PWV values proceeds ischemic changes in ECG and arterial changes in retina appear

Table 3 Comparison of average CAVI scores between CVD risk-free group and CVD high-risk groups for males

Age	20-29	30-39	40-49	50-59	60-69	70-75
<u>CVD risk-free group</u>						
Mean	6.69	7.12	7.59	8.06	8.73	9.35
SD	0.70	0.68	0.70	0.76	0.81	1.00
<u>Hypertension group</u>						
Mean	-	7.43	7.86	8.47	9.12	9.84
SD	-	0.86	0.87	1.01	1.12	1.15
t-value	-	4.24	4.75	6.51	4.06	2.07
p-value	-	p < 0.001	p < 0.001	p < 0.001	p < 0.001	p = 0.041
<u>Hypercholesterolemia & Hypertriglyceridemia group</u>						
Mean	-	6.95	7.74	8.42	8.97	9.71
SD	-	0.84	0.86	0.95	0.91	0.82
t-value	-	-2.39	2.33	5.05	2.34	1.62
p-value	-	p = 0.021	p = 0.023	p < 0.001	p = 0.022	P = 0.106
<u>Hyperglycemia group</u>						
Mean	-	7.25	7.76	8.68	9.41	10.01
SD	-	0.88	0.82	0.98	1.65	1.40
t-value	-	1.14	2.31	8.80	6.94	2.19
p-value	-	p = 0.123	p = 0.034	p < 0.001	p < 0.001	p = 0.042
<u>Ischemic changes group</u>						
Mean	-	-	7.81	8.79	9.29	9.97
SD	-	-	0.70	1.12	0.87	1.31
t-value	-	-	2.29	8.36	5.43	2.14
p-value	-	-	p = 0.033	p < 0.001	p < 0.001	p = 0.043
<u>Retinal artery changes group</u>						
Mean	-	-	8.09	8.77	9.16	9.97
SD	-	-	0.77	1.25	1.10	1.14
t-value	-	-	2.60	6.69	3.77	2.38
p-value	-	-	p = 0.014	p < 0.001	p < 0.001	p = 0.022
<u>All high-risk groups combined</u>						
Mean	6.39	7.18	7.79	8.49	9.12	9.80
SD	0.69	0.85	0.85	0.98	1.05	1.14
t-value	-1.87	1.26	3.96	7.20	4.48	1.93
p-value	p = 0.061	p = 0.209	p < 0.001	p < 0.001	p < 0.001	p = 0.054

Note: SD is standard deviation and - indicates that the number of cases was too small to obtain any meaningful results.

[40]. We have shown that the age-specific average CAVI scores of the ischemic changes group and of the retinal artery changes group were significantly greater than those of the CVD risk-free group (Tables 3, 4). This implies that CAVI scores reflect the extent of arteriosclerotic changes not only in medium-size and large-size arteries but also in small-size arteries.

We have shown that age-specific average CAVI scores of all CVD high-risk persons combined were significantly higher than those of the CVD risk-free group after 40 years of age (Tables 3, 4), indicating that the overall arteriosclerosis status of the CVD high-risk group was significantly worse than that of the CVD risk-free group. Because no difference in average CAVI


Table 4 Comparison of average CAVI scores between CVD risk-free group and CVD high-risk groups for females

Age	20-29	30-39	40-49	50-59	60-69	70-75
<u>CVD risk-free group</u>						
Mean	6.57	6.97	7.29	7.82	8.26	8.71
SD	0.66	0.63	0.66	0.70	0.72	0.74
<u>Hypertension group</u>						
Mean	-	7.02	7.73	8.16	8.89	9.46
SD	-	0.74	1.02	0.84	0.96	1.02
t-value	-	0.40	6.85	8.22	6.44	2.38
p-value	-	p = 0.346	p < 0.001	p < 0.001	p < 0.001	p = 0.023
<u>Hypercholesterolemia & Hypertriglyceridemia group</u>						
Mean	-	6.97	7.68	8.00	8.77	9.26
SD	-	0.78	1.21	0.78	0.90	0.74
t-value	-	-0.03	4.12	3.82	5.06	2.28
p-value	-	p = 0.914	p < 0.001	p < 0.001	p < 0.001	p = 0.034
<u>Hyperglycemia group</u>						
Mean	-	-	7.47	8.16	9.09	9.77
SD	-	-	0.86	0.74	1.04	0.79
t-value	-	-	1.74	5.23	6.57	3.69
p-value	-	-	p = 0.093	p < 0.001	p < 0.001	p < 0.001
<u>Ischemic changes group</u>						
Mean	-	-	7.49	8.10	8.75	9.39
SD	-	-	0.82	0.82	0.88	1.02
t-value	-	-	2.95	5.71	4.69	2.07
p-value	-	-	p = 0.004	p < 0.001	p < 0.001	p = 0.052
<u>Retinal artery changes group</u>						
Mean	-	-	8.03	8.34	9.36	9.32
SD	-	-	0.89	0.86	1.11	0.87
t-value	-	-	3.97	5.24	7.37	1.92
p-value	-	-	p < 0.001	p < 0.001	p < 0.001	p = 0.071
<u>All high-risk groups combined</u>						
Mean	6.88	6.93	7.58	8.12	8.81	9.34
SD	0.42	0.76	0.91	0.81	0.96	0.99
t-value	1.48	-0.56	6.25	8.05	5.96	2.09
p-value	p = 0.138	p = 0.578	p < 0.001	p < 0.001	p < 0.001	p = 0.038

Note: SD is standard deviation and - indicates that the number of cases was too small to obtain any meaningful results.

scores between the two groups was detected before 40 years of age, effective CAVI screening might be recommended for people age 40 and over.

With regard to the validity to use CAVI scores as an indicator of arteriosclerosis, Otsuka examined 72 deceased patients' ante-mortem PWV (which is a basis for deriving CAVI scores) and pathological changes measured by the diffuse fibrotic thickening, formation of atheroma and calcification in the wall of their aorta. He reported multiple regression coefficient R = 0.810 between PWV and scores of those pathological changes [41]. In addition, other researchers reported that CAVI scores were significantly associated with coronary



atherosclerosis [13], with carotid intima-media thickness and with homocysteine [14]. Thus, the use of CAVI scores derived from PWV values is valid to estimate the extent of arteriosclerosis.


VaSera VS-1000, which was used in our study, was designed to measure CAVI scores independent of blood pressure and CAVI scores represent the extent of arteriosclerosis between the aortic valve and the ankle. We have shown biological aging of the major artery by measuring CAVI scores in the CVD risk-free group and disease-related pathological aging of the major artery in the CVD high-risk group. CAVI scores allow us to evaluate the extent of arteriosclerosis in the major arteries between the aortic valve and the ankle, to screen persons with subclinical stage of CVD, and provide an opportunity to modify diet and lifestyle to improve CAVI scores as reported by Satoh et al [42]. Thus, the

use of CAVI scores potentially leads to savings on high treatment costs and to prolonging many productive lives.

There are some limitations in our study. First, the study design was cross-sectional and results were based on our observations at the time of screening. Secondly, our data did not include behavioral and lifestyle factors, although we consider that effects of such factors were reflected on clinical measurements related to CVD which we included. Currently we are examining the association between CAVI scores and lifestyle factors such as smoking, alcohol consumption, and body mass index, and will report results in the near future.

Conclusions

Our results imply that advancement of arteriosclerosis among men is greater in every age group than among



women. It is also implied that arteriosclerosis of the CVD high-risk group advances faster than that of the CVD risk-free group after 40 years of age. The baseline CAVI scores from the CVD risk-free group are useful for future studies as control values. The CAVI method is a useful tool to screen persons with moderate to advanced levels of arteriosclerosis.

Acknowledgements

The authors express their great appreciation to Ms. Mitsuko Nakata for her assistance in preparation of the manuscript. The reported work was partially supported by the grants from Smoking Research Foundation and Japan Health Promotion Foundation.

Author details

¹Pacific Rim Disease Prevention Center, P.O.Box 25444, Seattle, WA 98165-2344, USA. ²Department of Health Services, School of Public Health, University of Washington, Box 357660, Seattle, WA 98195-7660, USA. ³Japan Health Promotion Foundation, 1-24-4 Ebisu, Shibuya-ku, Tokyo, Japan. ⁴Department of Internal Medicine, Sakura Hospital Medical Center, Toho University, 546-1 Shizu, Sakura-shi, Chiba Prefecture, Japan.

Authors' contributions

TN, KS and KS conceived and designed the study. KS and NI acquired the data. TN and KS performed statistical analyses. TN and KS drafted the manuscript, all other authors revised critically and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 6 April 2011 Accepted: 10 August 2011

Published: 10 August 2011

References

1. Kung HC, Hoyert DL, Xu J, Murphy SL: Deaths: final data for 2005, Table 14. *National Vital Stat Rep* 2008, **56**:52-56.
2. Japan Health and Welfare Statistics Association: Trend of Nation's Health (Kokumin eisei no doukou). *J Health & Welfare Statistics* 2007, **54**:412-413.
3. Bramwell JC, Hill AV: The velocity of the pulse wave in man. *Proc Roy Soc of London Series B* 1922, **93**:298-306.
4. Bramwell JC, Hill AV: Velocity of transmission of the pulse wave and elasticity of arteries. *Lancet* 1922, **202**:891-892.
5. Bramwell JC, Hill AV, McSwiney BA: Velocity of transmission of the pulse wave in man as related to age as measured by the hot-wire sphygmograph. *Heart* 1923, **10**:233-249.

6. Bramwell JC, McDowall RJS, McSwiney BA: The variation of the arterial elasticity with blood pressure in man. *Proc Roy Soc of London Series B* 1923, **94**:450-454.
7. Bramwell JC, Dowing AC, Hill AV: The effect of blood pressure on the extensibility of the human artery. *Heart* 1923, **10**:289-300.
8. Hasegawa M: Fundamental research on human aortic pulse wave velocity. *Jikei Medical Journal* 1970, **85**:742-760.
9. Namekata T, Moore D, Suzuki K, Mori M, Hatano S, Hayashi C, Abe N, Hasegawa M: A study of the association between the aortic pulse wave velocity and atherosclerotic risk factors among Japanese Americans in Seattle, U.S.A. *Jpn J Pub Health* 1997, **44**:942-951.
10. Namekata T, Suzuki K, Arai C: Seattle Nikkei health study: Cross cultural surveys between Seattle and Japan. In *New Trends in Psychometrics*. Edited by: Shigematsu K, Okada A, Imaizumi T, Hoshino T. Tokyo, Universal Academy Press, Inc; 2008:339-346.
11. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). *J Atherosclerosis Thrombosis* 2006, **13**:101-107.
12. Hayashi G, Sato M, Niimi H, Handa H, Moritake K, Okumura A: Analysis of vascular wall constitutive law with finite deformation theory. *Medical Electronics & Biological Engineering* 1975, **13**:293-297.
13. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H: Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. *Circ J* 2008, **72**:598-604.
14. Kadota K, Takamura N, Aoyagi K, Yamasaki H, Usa T, Nakazato M, Maeda T, Wada M, Nakashima K, Abe K, Takeshima F, Ozono Y: Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. *Circ J* 2008, **72**:304-308.
15. Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M: Contradictory effects of β 1- and α 1- adrenergic receptor blocker on cardio-ankle vascular stiffness index (CAVI): CAVI is independent of blood pressure. *J Atheroscler Thromb* 2011, **18**:49-55.
16. Rose GA, Blackburn H, Gillum RF, Prineas RV, (eds.): *Cardiovascular Survey Methods* WHO Monograph Series No.56. Geneva, World Health Organization; 1982.
17. Scheie HG: Evaluation of ophthalmic changes of hypertension and arteriolar sclerosis. *Arch Ophthalmology* 1953, **49**:117-138.
18. Japan Atherosclerosis Society: *Guidelines for Diagnosis and Treatment of Atherosclerotic Disease for 2002* Tokyo, Japan Atherosclerosis Society; 2002.
19. Japan Diabetes Society: *Guideline for Treatment of Diabetes for 2004-2005* Tokyo, Bunkodo Publishing Co.; 2005.
20. Japan Society of Hypertension: *Guidelines for Treatment of Hypertension for 2004* Tokyo, Japan Society of Hypertension; 2005.
21. Noriyuki N, Mitsuru S, Kokoro S, Kazue N, Shigeki M, Toshio T, Kenji S, Kozo T: Associations between white blood cell count and features of the metabolic syndrome in Japanese male office workers. *Industrial Health* 2002, **40**:273-277.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Sibershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. *Circulation* 1998, **97**:1837-1847.
23. Denke MA, Grundy SM: Hypercholesterolemia in elderly persons: resolving the treatment dilemma. *Ann Intern Med* 1990, **112**:780-792.
24. Kodama K, Sasaki H, Shimizu Y: Trend of coronary heart disease and its relationship to risk factors in a Japanese population: a 26-year follow-up, Hiroshima/Nagasaki study. *Jpn Circ J* 1990, **54**:414-421.
25. Kannel WB: Fifty years of Framingham Study contributions to understanding hypertension. *J Hum Hypertens* 2000, **14**:83-90.
26. Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med* 1993, **153**:598-615.
27. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990, **335**:765-774.
28. Taquet A, Bonithon-Kopp C, Simon A, Levenson J, Scarabin Y, Malmejac A, Ducimetiere P, Guize K: Relations of cardiovascular risk factors to aortic pulse wave velocity in a symptomatic middle-aged women. *Eur J Epidemiol* 1993, **9**:298-306.
29. Bracher J, Asmar R, Djame S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. *Hypertension* 1999, **33**:1111-1117.
30. Verschuren WMM, Jacob DR, Bloenberg BPM, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Neoljkovic S, Nissinen A, Toshima H: Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five year follow-up of the Seven Countries Study. *JAMA* 1995, **274**:131-136.
31. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D: Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,622 men. *Lancet* 1986, **2**:933-936.
32. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. *N Engl J Med* 1993, **328**:313-318.
33. Assmann G, Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. *Am Heart J* 1988, **116**:1713-1724.
34. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993, **16**:434-444.
35. Lax H, Feinberg AW: Abnormalities of the arterial pulse wave in young subjects. *Circulation* 1959, **20**:1106-1110.
36. Christensen T, Neubauer B: Arterial wall stiffness in insulin-dependent diabetes mellitus. An in vivo study. *Acta Radiol* 1987, **28**:207-208.
37. Bjurulf P: Atherosclerosis in different parts of the arterial system. *Am Heart J* 1964, **68**:41-50.
38. Scott RF, Daoud AS, Wortman B, Morrison ES, Jarmolych J: Proliferation and necrosis in coronary and cerebral arteries. *J Atheroscler Res* 1966, **6**:499-509.
39. Kagan AR, Uemura K: Atherosclerosis of the aorta and coronary arteries in five towns. Material and methods. *Bull WHO* 1976, **53**:489-499.
40. Suzuki K, Mori M, Abe N, Arai C, Ooyama T: Epidemiological Studies of Arteriosclerosis (1): Association of aortic pulse wave velocity with hypertension, arteriolar sclerotic changes in the retina, and ischemic ECG changes. *J Jpn Atheroscler Soc* 1996, **23**:715-720.
41. Otsuka F: A study of the relationship between pulse wave velocity of human aorta and its postmortem histopathology. *Tokyo Jikei Medical College Journal* 1973, **88**:11-16.
42. Satoh N, Shimatsu A, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Ooishi M, Kotani K, Ogawa Y: Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. *Hypertens res* 2008, **31**(10):1921-30.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2261/11/51/prepub>

doi:10.1186/1471-2261-11-51

Cite this article as: Namekata et al.: Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. *BMC Cardiovascular Disorders* 2011 **11**:51.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Review

Cardio-Ankle Vascular Index (CAVI) as a Novel Indicator of Arterial Stiffness: Theory, Evidence and Perspectives

Kohji Shirai¹, Noriyuki Hiruta², Mingquiang Song^{1,3}, Takumi Kurosu⁴, Jun Suzuki⁴, Takanobu Tomaru⁴, Yoh Miyashita¹, Atsuto Saiki¹, Mao Takahashi¹, Kenji Suzuki⁵ and Masanobu Takata⁶

¹Internal Medicine, Sakura Hospital, School of Medicine, Toho University, Chiba, Japan

²Clinical Pathology, Sakura Hospital, School of Medicine, Toho University, Chiba, Japan

³Endocrinological Division, Weihai municipal Hospital, Weihai, China

⁴Clinical Functional Physiology Division, Sakura Hospital, School of Medicine, Toho University, Chiba, Japan

⁵Japan Labor and Welfare Association, Tokyo, Japan

⁶Internal Medicine, Toyama Teishin Hospital, Toyama, Japan

The cardio-ankle vascular index (CAVI) is a new index of the overall stiffness of the artery from the origin of the aorta to the ankle. The most conspicuous feature of CAVI is its independence of blood pressure at the time of measurement.

CAVI increases with age and in many arteriosclerotic diseases, such as coronary artery disease, carotid arteriosclerosis, chronic kidney disease and cerebrovascular disease, and is related to many coronary risk factors, such as hypertension, diabetes mellitus, dyslipidemia and smoking. Furthermore, CAVI decreases by controlling diabetes mellitus and hypertension, and also by abstaining from smoking. This suggests that CAVI is a physiological surrogate marker of athero- or arteriosclerosis, and also might be an indicator of lifestyle modification.

Recently, it has been reported that CAVI and several left ventricular functions are co-related, suggesting a connection between the heart muscle and vascular function.

This review covers the principles of CAVI and our current knowledge about CAVI, focusing on its roles and future outlook.

J Atheroscler Thromb, 2011; 18:924-938.

Key words; Arterial stiffness, Cardio-ankle vascular index, Hypertension, Diabetes mellitus, Arteriosclerosis

Introduction

Many previous studies have demonstrated the significance of arterial stiffness as a surrogate marker for determining the prognosis of cardiovascular disease¹⁻³. Aortic stiffness is based on the structural changes occurring prior to plaque or thrombus formation in muscular and elastic vessels. Increased arterial stiffness is seen in patients with coronary risk factors

such as hypertension⁴, diabetes mellitus⁵ and hyperlipidemia⁶; therefore, it is meaningful to estimate the degree of arteriosclerosis by examining arterial stiffness in order to prevent cardio- and cerebrovascular events⁷.

Many methods have been designed to assess arterial stiffness. Among them, pulse wave velocity (PWV)¹⁻⁷, augmentation index⁸, stiffness parameter β ^{9, 10}, and carotid-femoral PWV (cfPWV)¹¹ have been proposed as markers of arterial stiffness. In 2002, brachial-ankle pulse wave velocity (baPWV) was proposed as a marker of vascular damage¹², and was reported to be a predictive factor of coronary artery disease¹³; however, PWV is known to depend on blood pressure at the time of measurement¹⁴. Hence, the validity of PWV in reflecting actual arterial stiff-

Address for correspondence: Kohji Shirai, Department of Internal Medicine, Sakura Hospital, School of Medicine, Toho University, 564-1 Shimoshizu, Sakura-shi, Chiba 285-8741, Japan

E-mail: kshirai@kb3.so-net.ne.jp

Received: January 7, 2011

Accepted for publication: April 22, 2011




Fig. 1. CAVI and its measurement.

With the patient lying supine, an electrocardiogram and heart sounds are monitored. PWV from the heart to the ankle is obtained by measuring the length from the origin of the aorta to the ankle, and by calculating $T = t_b + t_{ba}$. Blood pressure is measured at the brachial artery.

Ps: systolic blood pressure, Pd: diastolic blood pressure, PWV: pulse wave velocity, ΔP : $P_s - P_d$, ρ : blood density, ΔP : pulse pressure, L: length from the origin of the aorta to the ankle, T: time taken for the pulse wave to propagate from the aortic valve to the ankle, t_b : time between the rise of brachial pulse wave and the rise of ankle pulse wave, t_{ba} : time between aortic valve closing sound and the notch of brachial pulse wave, t'_{ba} : time between aortic valve opening sound and the rise of brachial pulse wave¹⁸⁾.

ness is questionable, and this parameter is unsuitable to evaluate the role of hypertension control with drugs in the arterial wall.

In 1970, Hasegawa¹⁵⁾ established a method of measuring heart-femoral PWV (hfPWV) corrected for blood pressure. In this method, hfPWV is corrected by adjusting diastolic pressure to 80 mmHg. The usefulness of corrected hfPWV has been reported in several studies^{16, 17)}; however, this examination can be difficult to conduct, especially in women, because the inguinal region has to be palpated to detect the pulse.

In 1980, Hayashi *et al.*⁹⁾ developed a calculation for stiffness parameter $\beta = \ln(P_s/P_d) \cdot D/\Delta D$, where P_s is systolic, P_d is diastolic blood pressure, D is the diameter of the artery, and ΔD is the change in arterial diameter according to blood pressure difference. In simple terms, stiffness parameter β represents the blood pressure change required to expand the diameter of the artery; therefore, this value does not depend on blood pressure. Kawasaki *et al.*¹⁰⁾ succeeded in

measuring β in the cervical artery using an echo-phase tracking system. A limitation of stiffness parameter β is that it is applicable only to a local segment of the artery.

The cardio-ankle vascular index (CAVI) was developed with the objective of obtaining an arterial stiffness index that is not affected by blood pressure at the time of measurement, and which reflects the stiffness of a considerable length of the artery¹⁸⁾.

Theory and Principle of CAVI

CAVI reflects the stiffness of the whole arterial segment composed of the aorta, femoral artery and tibial artery (Fig. 1, from ref. 18). CAVI can be calculated from PWV at the origin of the aorta to the ankle portion of the tibial artery, and systolic and diastolic blood pressures measured at the upper brachial artery. This index was originally derived from stiffness parameter β proposed by Hayashi⁹⁾ and Kawasaki *et*




Fig. 2. Deduction of CAVI from the stiffness parameter β by applying Bramwell-Hill's equation.

The CAVI equation originated from stiffness parameter $\beta = \ln (Ps/Pd) \cdot (D/\Delta D)^9, 10)$. $D/\Delta D$, derived from a modification of Bramwell-Hills equation¹⁹⁾, was substituted in the equation of stiffness parameter β . CAVI was then deduced.

al.¹⁰⁾, with application of Bramwell-Hill's equation¹⁹⁾.

Here, the principle of the CAVI formula is described briefly (Fig. 2):

$$CAVI = a \{ (2\rho/\Delta P) \times \ln(Ps/Pd) PWV^2 \} + b$$

----- CAVI formula

where, P_s is systolic blood pressure, P_d is diastolic blood pressure, PWV is pulse wave velocity from the origin of the aorta to tibial artery at the ankle through the femoral artery, ΔP is $P_s - P_d$, ρ is blood density, and a and b are constants.

The above equation is derived as follows:

$$CAVI \text{ is essentially } \beta, \text{ and } \beta = \ln (Ps/Pd) \cdot D/\Delta D$$

where D is the diameter of the artery, ΔD is the change in the diameter of the artery according to pressure change^{9, 10)}.

$D/\Delta D$ can be obtained from a modification of the Bramwell-Hill's equation¹⁹⁾:

$$PWV^2 = \Delta P / \rho \cdot V / \Delta V$$

----- equation 1

where ΔP is pulse pressure, V is blood vessel volume, ΔV is the change in V , and ρ is blood density $V/\Delta V$ can be expressed in terms of D and ΔD as

follows:

$$\begin{aligned} V/\Delta V &= (\pi L(D/2)^2) / [\pi L((D + \Delta D)/2)^2 - \pi L(D/2)^2] \\ &= D^2 / [D^2 + 2D \Delta D + \Delta D^2 - D^2] \\ &= D^2 / (2D\Delta D + \Delta D^2) \end{aligned}$$

Since ΔD^2 is negligibly small compared with $2D\Delta D$, it is ignored. The equation becomes:

$$V/\Delta V = D^2 / 2D\Delta D = D / 2\Delta D$$

----- equation 2

Thus, $V/\Delta V$ in equation 1 can be replaced by $D/2\Delta D$. Equation 1 becomes:

$$\begin{aligned} PWV^2 &= \Delta P / \rho \cdot V / \Delta V = \Delta P / \rho \cdot D / 2\Delta D, \text{ and} \\ D/\Delta D &= 2\rho / \Delta P \cdot PWV^2 \end{aligned}$$

----- equation 3

Next, equation 3 is substituted into the equation of stiffness parameter β to obtain the new β (β').

$$\begin{aligned} \beta' (= CAVI) &= \ln(Ps/Pd) \cdot (D/\Delta D) \\ &= \ln(Ps/Pd) \cdot 2\rho / \Delta P \cdot PWV^2 \end{aligned}$$

This new index was named the cardio-ankle vascular index (CAVI), which reflects the overall stiffness of the aorta, femoral artery and tibial artery, and is theoretically not affected by blood pressure.

Thus, CAVI originated from stiffness parameter




Fig.3. Effects of the β_1 blocker, metoprolol and α_1 -blocker, doxazosin, on CAVI and baPWV.

With the administration of a selective β_1 adrenergic blocker, metoprolol (80 mg), both systolic and diastolic blood pressures decrease and baPWV also decreases, but CAVI does not change²³⁾ (Fig. 3A). This study indicates that CAVI is independent of blood pressure at the time of measurement. Furthermore, with the administration of a selective α_1 -adrenergic receptor blocker, doxazosin, both systolic and diastolic blood pressures decreased and CAVI decreased as well as baPWV (Fig. 3B), indicating that CAVI decreased with relaxation of the smooth muscles induced by α_1 -adrenergic receptor blocker.

$\beta = \ln(P_s/P_d) \cdot (D/\Delta D)$, and is calculated from PWV for a given length of the artery and ΔP , instead of diameter change ($D/\Delta D$).

The Rationale for CAVI and Independence on Blood Pressure

There remains a question of whether it is valid to apply Bramwell-Hill's equation to the equation of stiffness parameter β , which is essentially applied to a portion of the aorta. Takaki *et al.*²⁰⁾ provided evidence for the validity of CAVI by showing a positive correlation between stiffness parameter β of the aorta and CAVI. They measured β of the thoracic descending aorta using transesophageal echocardiography, and reported a positive correlation between aortic stiffness parameter β and CAVI ($r=0.67, p<0.01$), suggesting that the application of Bramwell-Hill's equation to stiffness parameter β equation is appropriate.

Next, the most conspicuous feature of CAVI is its theoretical independence on the blood pressure at the time of measurement; however, this theory has not been proven experimentally. Several reports^{18, 20-22)} showed that CAVI is less dependent on blood pressure than PWV, but these results do not necessarily mean that CAVI is independent on blood pressure at the time of measurement. We studied this point using a selective β_1 receptor blocker²³⁾. Metoprolol is a selective β_1 blocker and is known to reduce the contraction of the heart muscle and decrease blood pressure without affecting the tone of the arterial wall. When metoprolol was administered to 12 men, baPWV decreased over 6 hours, but CAVI did not change (Fig. 3A). This result clearly demonstrates that CAVI is not influenced by blood pressure at the time of measurement.

Thus, CAVI can be used to compare the properties of the artery, even though blood pressure may

Table 1. CAVI in arteriosclerotic diseases and in coronary risks

	CAVI value	Reference
Coronary artery diseases [Acute coronary disease]	↑↑	Nakamura ²⁴⁾ , Izuhara ²⁵⁾ , Miyoshi ²⁶⁾ , Horinaka ²⁷⁾ [Sairaku ²⁹⁾]
Intima media thickness of cervical artery	↑	Nakamura ²⁴⁾ , Iyata ²²⁾ , Takaki ^{20, 28)} , Izuhara ²⁵⁾ , Miyoshi ²⁶⁾ , Okura ³⁶⁾ , Sairaku ²⁹⁾ , Horinaka ²⁷⁾ , Hayashi ³⁸⁾
Chronic kidney disease [Mortality rate in patients with hemodialysis]	↑↑	Izuhara ²⁵⁾ , Kobuzono ³⁰⁾ , Takenaka ³¹⁾ , Nakamura ³²⁾ , Ueyama ³³⁾ , Satoh-Asahara ³⁶⁾ [Kato ⁴⁰⁾]
Cerebral infarction, Dementia	↑	Yamamoto ³⁹⁾
Metabolic syndrome	↑	Satoh ⁵⁵⁾
Diabetes mellitus	↑	Iyata ²²⁾ , Izuhara ²⁵⁾ , Okura ³⁷⁾
Hypertension	↑	Kubozono ²¹⁾ , Okura ³⁷⁾ , Takaki ⁴²⁾ , Kadota ⁴³⁾
Dyslipidemia	↑	Takaki ²⁸⁾
Smoking	↑	Kubozono ²¹⁾ , Noike ⁶²⁾
Obstructive sleep apnea syndrome	↑	Kumagai ⁶⁰⁾

change. CAVI permits, for the first time, analysis of the effect of antihypertensive treatments on arterial stiffness.

Factors Affecting CAVI (Table 1)

(1) Aging and Sex

The effects of age and sex on CAVI in healthy persons living in major cities throughout Japan were studied. Among the subjects, 32,627 persons who were receiving an annual health check, healthy persons without risk factors were selected. Their ages ranged from 20 to 79 years. The results are shown in Fig. 4. The VaSera VS-1500 (Fukuda Denshi Co., Tokyo) was used to measure CAVI. CAVI of healthy men without cardiovascular risk factors increased almost linearly with age from 20 to 70 years. CAVI of men is higher than that of women in almost all age groups by 0.2. The linear regression equation is $CAVI = 5.43 + 0.053 \times \text{age}$ for men, and $CAVI = 5.34 + 0.049 \times \text{age}$ for women. The rate of increase was nearly 0.5 per 10 years in men and women.

(2) Arteriosclerotic Diseases

Confirming that CAVI is an indicator of arteriosclerosis is no easy task, because quantitative measurement of arteriosclerosis is difficult *in vivo*. To confirm that CAVI reflects the degree of arteriosclerosis, the gross appearance of the aorta at postmortem was com-

pared with CAVI, which was measured when the subjects were alive. Fig. 5 shows some typical examples.

The aorta of a 50-year-old woman showed almost no atheroma, and the CAVI was 7.0. The aortas of 74- and 76-year-old men showed advanced stages of arteriosclerosis. The CAVI was 11.0 in both. As described below, the cutoff point of CAVI is 9.0. Post-mortem gross appearance of aortas thus supports the notion that CAVI reflects the progression of arteriosclerosis. CAVI in various arteriosclerotic diseases is described in the next section.

A. Coronary Artery Disease

Nakamura *et al.*²⁴⁾ reported that CAVI increases as the number of vessels with stenosis (>75%) increases. Stepwise ordinal logistic regression analysis using mean intimal-media thickness (IMT), maximum IMT, plaque score and CAVI as independent variables identified only CAVI as positively related to the severity of coronary atherosclerosis. Receiver operating characteristic curve analysis (ROC analysis) of mean IMT, max IMT, plaque score and CAVI showed that the area under the ROC defined by CAVI was the greatest among the 3 scores²⁴⁾. CAVI might be more useful for discriminating the probability of coronary atherosclerosis by high-resolution B-mode ultrasonography. The cutoff point of CAVI for the presence of coronary stenosis was 8.91.

Izuhara *et al.*²⁵⁾ reported that CAVI is indepen-




Fig. 4. CAVI in aging and sex.

The effects of age and sex on CAVI were studied in 32,627 residents of major cities throughout Japan, who received an annual health check. They were healthy and had no coronary risk factors. CAVI increases with age almost linearly from 20 to 70 years in males and females by almost 0.5 over 10 years. CAVI of men is higher than that of women in almost all age groups by 0.2.

dently associated with the severity of coronary atherosclerosis. Recently, Miyoshi *et al.*²⁶⁾ also supported a correlation between CAVI and coronary atherosclerosis. Horinaka *et al.*²⁷⁾ reported that CAVI is superior to baPWV in predicting coronary artery disease. Takaki *et al.*²⁸⁾ confirmed that CAVI is better than baPWV for predicting the presence of coronary and cervical arteriosclerosis. Sairaku *et al.*²⁹⁾ reported that CAVI is significantly and independently higher in patients with acute coronary disease than in those with stable angina pectoris.

B. Chronic Kidney Disease and Hemodialysis Patients

Several studies examined the relationship between CAVI and renal disease. Kubozono *et al.*³⁰⁾ reported that CAVI correlates independently with the estimated glomerular filtration rate in the Japanese general population. Takenaka *et al.*³¹⁾ found that CAVI is high in end-stage renal diseases. Nakamura *et al.*³²⁾ reported that CAVI is closely associated with cystatin C levels, suggesting a significant role of arterial stiffness in renal insufficiency. Ueyama *et al.*³³⁾ also reported that CAVI is high in hemodialysis patients.

Ichihara *et al.*³⁴⁾ showed that CAVI was higher in

patients with kidney failure and reported a correlation between the severity of arterial fibrosis and CAVI. Shen *et al.*³⁵⁾ used CAVI to predict the risk of *de novo* arterial stiffness in patients on chronic dialysis.

Recently, Satoh-Asahara *et al.* reported that CAVI was higher in metabolic syndrome, and negatively correlated with eGFR and S-CysC, and body weight reduction reduced CAVI in obese patients with metabolic syndrome³⁶⁾.

The positive correlation between chronic kidney disease and CAVI may be explained by the fact that arteriosclerosis is a systemic disease involving the renal and central arteries simultaneously. Another possible reason is that the kidney of a person with arteriosclerosis secretes many factors such as renin, which promotes systemic arteriosclerosis.

C. Intimal Thickness of Carotid Artery

Nakamura *et al.*²⁴⁾ reported that CAVI correlates positively with maximum IMT and the plaque score in the carotid arteries. Okura *et al.*³⁷⁾ reported that CAVI correlated positively with IMT ($r=0.360$, $p=0.0022$) and the stiffness parameter β ($r=0.270$, $p=0.0239$) in 70 hypertensive patients. Similarly,




Fig. 5. Appearance of the abdominal aorta at postmortem study and CAVI.

Top: The aorta was from a 50-year-old woman who died of pancreatic cancer. The surface of the abdominal aorta is smooth and atheroma is scarcely observed.

Bottom: The abdominal aortae were obtained from a 74-year-old man and a 76-year-old man. Both aortae show an advanced stage of atherosclerosis. CAVI of both individuals is 11.0. Nakamura *et al.*²⁴⁾ reported that CAVI=9.0 was the cut-off value for the presence of coronary artery stenosis.

Takaki *et al.*²⁰⁾ reported a significant correlation between CAVI and IMT ($r=0.48$, $p<0.01$). Izuhara *et al.*²⁵⁾ concluded that high CAVI implies the progression of carotid arteriosclerosis, and that CAVI may be more closely linked with arteriosclerosis than baPWV. Hayashi³⁸⁾ reported that D-dimer is significantly higher in the arteriosclerotic group (CAVI >8.0 and IMT >1.1 mm). The combination of CAVI and IMT could be a more significant predictor of thrombosis in highly atherosclerotic patients.

D. Cerebrovascular Events and Dementia

In a four-year follow-up study, Yamamoto *et al.* reported³⁹⁾ that community-dwelling elderly people with a high CAVI value are at a greater risk of cognitive decline. Preliminary study on the relationship between CAVI and cerebrovascular events has been conducted, but not yet published.

E. Survival Prognosis

Kato *et al.*⁴⁰⁾ conducted a 39-month follow-up study on the mortality rate of 194 hemodialysis

patients. They found that a small reduction in the ankle-brachial index is associated with increased mortality in patients on chronic hemodialysis, while CAVI and baPWV are not associated with mortality.

An on-going study of CAVI in predicting survival prognosis in patients on chronic hemodialysis has started to report preliminary findings, but full papers have not yet been published. Time is required to reach a conclusion.

CAVI and Coronary Risk Factors

A. Hypertension

CAVI is not affected by blood pressure at the time of measurement^{18, 23)}; therefore, the effect of blood pressure on the properties of the arterial wall can be evaluated by CAVI. Okura *et al.*³⁷⁾, Takaki *et al.*⁴¹⁾, and Kadota *et al.*⁴²⁾ reported that CAVI correlates with blood pressure. These reports were the first to demonstrate the real correlation between blood pressure itself and arterial wall stiffness.

Interestingly, when sunitinib maleate was administered to a patient, CAVI started to increase before

Table 2. Improving factors or treatment for CAVI

Treatments	CAVI value change	Reference
Weight reduction	↓	Satoh ⁵⁵⁾
Blood glucose control	↓	Nagayama ⁵¹⁾ , Ohira ⁵²⁾
Hypertension control		
Angiotensin II receptor blocker	↓	Uehara ⁴⁴⁾ , Kinouchi ⁴⁵⁾ , Bokuda ⁴⁶⁾
Calcium channel antagonist	↓	Sasaki ⁴⁷⁾
Lipid-lowering agents		
Statin	↓	Miyashita ⁵⁴⁾
Ezetimib	↓	Miyashita ⁵⁶⁾
Eichsapentanoic acid	↓	Satoh ⁵⁵⁾
Stop smoking	↓	Noike ⁶²⁾
Continuous pulmonary assistance	↓	Lü ⁶¹⁾

blood pressure increased⁴³⁾. This finding suggests that CAVI may reflect the stress on the artery induced by sunitinib maleate before hypertension occurs. CAVI may be useful to predict the occurrence of hypertension, but more detailed studies are required.

Several blood pressure-lowering agents have been reported to decrease CAVI (Table 2). CAVI was decreased by angiotensin II receptor antagonists^{44,46)}. Among calcium channel blockers, efonidipine decreased CAVI in diabetic patients⁴⁷⁾. When the calcium channel blocker amlodipine and the angiotensin II receptor blocker (ARB) olmesartan were compared, olmesartan decreased CAVI to a greater extent even though both agents effected blood pressure to a similar decrease⁴⁸⁾. Bokuda *et al.*⁴⁶⁾ reported that candesartan decreased CAVI much more than calcium channel blockers.

Diuretics are known to decrease blood pressure, but may exacerbate insulin resistance. Ishimitsu *et al.*⁴⁹⁾ reported that the combination of olmesartan and azelnidipine has advantages over the combination of olmesartan and a thiazide with respect to avoiding increased arterial stiffness in patients with moderate hypertension. A tablet combining losartan and hydrochlorothiazide has been found to decrease CAVI⁵⁰⁾. These clinical data suggest that CAVI might discriminate the causes of hypertension and also the mechanism of blood pressure-lowering agents. For example, the causes of hypertension might be divided into 3 categories: increased heart muscle contraction; increased resistance of the peripheral artery; increased circulatory blood volume. CAVI is supposed to reflect the second effect; therefore, monitoring CAVI would contribute to clarifying or identifying the cause of

hypertension. Moreover, monitoring CAVI during the administration of different antihypertensive drugs may contribute to elucidating the patho-physiology during various treatments for hypertension. To confirm this hypothesis, further studies are required.

B. Diabetes Mellitus

CAVI is reported to be high in patients with diabetes mellitus²²⁾. Most studies found that diabetes mellitus is a potent factor that increases CAVI in aged persons.

Recent studies have shown that insulin therapy decreases CAVI while lowering the blood glucose level (Table 2). Nagayama *et al.*⁵¹⁾ reported that glimepiride decreases CAVI accompanied by an improved glucose level. Ohira *et al.*⁵²⁾ reported that insulin injection also decreases CAVI concomitant with a decrease in the blood glucose level. These clinical observations may suggest that CAVI is a sensitive physiological index for monitoring the stress on the arterial wall by high blood glucose, probably due to glucose toxication. A high glucose level may modulate the arterial wall to increase stiffness within a relatively short time, resulting in an increase in CAVI. This increase may be reversible, because blood glucose control decreases CAVI in a rather short period. Further studies are required to clarify the mechanism by which high glucose or glucose toxication modulates arterial wall stiffness.

C. Dyslipidemia

CAVI and dyslipidemia are not closely connected; however, Takaki⁵³⁾ reported that CAVI is related to the LDL-cholesterol level and also the total

cholesterol/HDL-cholesterol ratio. Hyperlipidemia per se does not immediately increase arterial wall stiffness. After accumulation of cholesterol in the lipid pool, oxidative stress generates oxysterol, which is highly toxic and enhances inflammation, followed by the onset of atherosclerosis; therefore, CAVI may increase under certain conditions in dyslipidemia.

The effects of lipid-lowering agents have been reported (Table 2). Miyashita *et al.*⁵⁴ reported that pitavastatin treatment decreased CAVI after one year. Eicosapentaenoic acid reduces CAVI in association with decreased serum amyloid A-LDL in metabolic syndrome⁵⁵. Ezetimibe monotherapy decreases CAVI in type 2 diabetic patients⁵⁶. The arterial stiffness-improving effect of lipid-lowering agents might be due to some functional modulation in addition to organic pathologic changes.

D. Metabolic Syndrome, Obesity and Weight Reduction

Metabolic syndrome prevails worldwide. Visceral fat accumulation has been suggested to induce glucose intolerance, hypertension, and dyslipidemia, such as low HDL-cholesterol and hypertriglyceridemia⁵⁷. These conditions are believed to be due to insulin resistance. High CAVI is associated with obesity and metabolic syndrome⁵⁸. Adiponectin, which is implicated in insulin sensitivity and considered to be a biomarker of metabolic syndrome, is related negatively to CAVI⁵⁹. The above findings indicate that CAVI could be a good marker of macroangiopathy in metabolic syndrome, for which there are few initial signs and symptoms.

Weight reduction is known to improve metabolic syndrome, and Satoh *et al.*⁵⁸ reported that weight reduction through diet and exercise therapy over a 3-month period significantly decreased CAVI values in parallel with increasing adiponectin. CAVI may be useful for evaluating and managing the cardiovascular risks of patients with metabolic syndrome.

E. Sleep Apnea Syndrome

CAVI has been reported to be high in sleep apnea syndrome⁶⁰ and to decrease with continuous positive airway pressure (CPAP)⁶¹. The mechanism by which CAVI increases in sleep apnea syndrome may be due to the activation of sympathetic nerves by sleep apnea, which consequently increases arterial wall stiffness.

Interestingly, since CAVI decreases after CPAP therapy in patients with sleep apnea syndrome, CAVI could be used as an efficient marker for CPAP therapy.

F. Smoking

Kubozono *et al.*²¹ reported that CAVI was high in smoking subjects. Noike *et al.*⁶² reported that smoking increases CAVI but, interestingly, CAVI decreases after stopping smoking. This reversible change of CAVI might imply that smoking contracts the arterial wall of smooth muscle cells. CAVI may be a good indicator to enhance the motivation of persons who are trying to stop smoking.

G. CAVI in Inflammatory Vascular Disease

Inflammatory diseases of the arterial wall are known to be associated with accelerated atherosclerosis. Detection of increased arterial stiffness in patients in the early stage of large vessel vasculitis may be possible by measuring CAVI. Recent case reports showed that CAVI was high in patients with systemic lupus erythematosus⁶³ and aortitis syndrome^{64, 65}, and the augmented CAVI was decreased by immunosuppressive therapy⁶⁵. These results indicate that CAVI reflects the presence of an inflammatory reaction of arteries in the whole body. The mechanism by which CAVI increases in such conditions is not known. Inflammatory cytokines generated in the arterial wall might induce the contraction of smooth muscle cells or induce remodeling of the arterial wall, but detailed studies on these issues are required. Wakabayashi *et al.*⁶⁶ reported that CAVI is associated with acute phase reactants, such as C-reactive protein, amyloid A protein, sialic acid, fibrinogen and white blood cells in type 2 diabetes mellitus.

H. Miscellaneous Diseases and/or Conditions

Besides arteriosclerosis-related disorders, CAVI is changed in many diseases and/or conditions. Torisu *et al.*⁶⁷ reported that CAVI was significantly higher in atrophic gastritis-positive patients than in atrophic gastritis-negative patients, even after adjusting for possible confounding factors (8.59 ± 1.20 vs. 8.27 ± 1.19 , $p = 0.022$).

Wu *et al.*⁶⁸ reported that personal exposure to ozone was associated with a 4.8% increase in CAVI, suggesting that vascular function may be more sensitive to air pollutants. Those reports may indicate that many unidentified factors involved in the development of arteriosclerosis could be evaluated using CAVI in the future.

Relationship between CAVI and Cardiac Functions

Mizuguchi⁶⁹ reported that arterial stiffness is associated with left ventricular diastolic function in




Fig. 6. Atheroma formation with coronary risk factors and CAVI.

The process of athero- and arteriosclerosis is supposed as follows. A lipid pool is formed with infiltration of LDL, small dense LDL and remnants. Oxidation of lipids provokes inflammation. Then, smooth muscle cells proliferate to form intimal thickening. Inflammatory reaction gathers macrophages, which degrade the matrix, and also induce smooth cell apoptosis. Then, plaque rupture occurs and thrombus is formed. Risk factors are involved in various steps. Some target the endothelial cells and produce injuries. Some promote oxidation stress in the arterial wall. Others target medial smooth muscle cells, increasing contraction or provoking cell proliferation. Interestingly, all these injurious reactions seem to be integrated in CAVI.

patients with cardiovascular risk factors. They demonstrated that CAVI correlated positively with peak early diastolic trans-mitral flow velocity, E/A, and the deceleration time of early diastolic transmitral flow velocity (E-DT). Sakane *et al.*⁷⁰⁾ showed that CAVI was significantly higher in patients with reduced left ventricular (LV) diastolic function than in those with normal LV diastolic function (9.0 ± 1.1 versus 8.5 ± 1.1 , $p = 0.009$), and concluded that increased CAVI is independently associated with LV diastolic dysfunction in patients with preserved systolic function. Masugata *et al.*⁷¹⁾ measured the peak early diastolic mitral annular velocity (E') as an index of LV diastolic function using tissue Doppler echocardiography, and demonstrated that E' correlates with CAVI ($r = -0.518$, $p < 0.001$). They also reported that aortic annular velocity assessed by tissue Doppler echocardiography is a potential parameter of arterial stiffness⁷²⁾. These results indicate that left ventricular diastolic function correlates with vascular elasticity indicated by CAVI. In other words, the state of high CAVI of the elastic and muscular

arterial wall might worsen left ventricle diastolic function; therefore, measuring CAVI may be important when considering diagnostic and therapeutic strategies aiming at cardiac protection^{69, 70)}. Further investigations are needed to confirm a causal relationship.

Summary

What is CAVI? What is the Outlook of CAVI a Marker of Arteriosclerosis?

A high CAVI is observed in many arteriosclerotic diseases, such as coronary artery disease, carotid arteriosclerosis, chronic kidney disease and cerebrovascular disease, and is related to many coronary risk factors, such as hypertension, diabetes mellitus, dyslipidemia and smoking, as shown in **Table 1**. These clinical data indicate that CAVI can be a surrogate marker of athero- or arteriosclerosis. Furthermore, CAVI decreases in a relatively short period by various treatments, as shown in **Table 2**. Furthermore, vasodilators such as doxazosin and α 1- adrenergic receptor

Table 3. Cardiac Function and CAVI

Left ventricular diastolic function	CAVI value	Reference
Left ventricular ejection fraction	➔	Sakane ⁷⁰⁾ , Mizuguchi ⁶⁹⁾
Left atrial dimension	⬆	Sakane ⁷⁰⁾ , Mizuguchi ⁶⁹⁾
Peak early diastolic velocity (E)	⬆	Sakane ⁷⁰⁾ , Mizuguchi ⁶⁹⁾ , Masugata ⁷¹⁾
Peak atrial diastolic velocity (A)	⬆	Sakane ⁷⁰⁾
E/A	⬆	Sakane ⁷⁰⁾ , Mizuguchi ⁶⁹⁾
Deceleration time of E velocity (DcT)	➔	Sakane ⁷⁰⁾ , Mizuguchi ⁶⁹⁾





Fig. 7. Roles of CAVI in resistance or compliance of the artery as a surrogate marker of arteriosclerosis and also vascular function.

CAVI reflects the resistance or compliance of the artery; therefore, CAVI indicates the degree of sclerosis of the artery, and also reflects vascular function which keeps the heart functioning and maintains peripheral steady blood flow as a Windkessel. The former is a surrogate marker of arteriosclerosis and smooth muscle contraction. The latter might protect or improve left ventricular function, and maintain steady blood flow. To confirm this, many more basic and clinical studies are required.

blocker decrease CAVI in 1 to 5 hours, concomitant with a decrease in blood pressure (Fig. 3B, Ref. 23), indicating that smooth muscle cell contraction is an important determinant of CAVI, in addition to the organic components of the arterial wall, summarized in Fig. 6.

Many risk factors, such as hyperglycemia, hypertension, dyslipidemia (small dense LDL, remnants, LDL) and smoking, act injuriously on the arterial wall

in their own ways, including endothelial dysfunction, oxidative stress and provoking inflammation. One method is by promoting organic sclerosing process and an other is by promoting the contraction of smooth muscle cells. Both processes might be integrated into CAVI.

In the future, CAVI might be useful to compare the severity of arteriosclerosis in people in different districts or countries, and might be useful to find risk

factors in each^{73,74}). CAVI might also be a good physiological surrogate marker of lifestyle change, such as ceasing smoking, control of blood pressure and glucose level, and resultantly might be expected to contribute to the prevention of arteriosclerotic diseases.

As a Marker of Vascular Function

The circulation system is composed of the heart, large- and medium-sized arteries and microvessels. Pulsatile movement of the heart efficiently transports the blood to peripheral organs with the aid of vascular function; that is, the arteries dilate in the systolic phase and contract during the diastolic phase. While this windkessel action is ascribed to vascular compliance or resistance¹⁾, an index to reflect this function has not been available. Several reports have confirmed that CAVI and left ventricular functions are related, as shown in **Table 3**⁶⁹⁻⁷¹⁾. Furthermore, the α 1-aderenergic receptor blocker doxazosin, which dilates the peripheral arteries by decreasing resistance, decreases CAVI as described above²³⁾. These results indicate that CAVI reflects the compliance or resistance of the artery, and may have a protective effect on the left ventricle, as shown in **Fig. 7** (lower panel).

The possibility that CAVI plays a role in the analysis of systemic circulation as a marker of peripheral resistance or compliance deserves to be evaluated. In this context, CAVI may open a new field in the study of systemic circulation.

Acknowledgments

We greatly appreciate Dr. Oyama, Dr. Endo, Dr. Ohira, Dr. Nagayama, Dr. Kawana, Dr. Bann, Dr. Nagumo and Dr. Yamaguti in the Department of Internal Medicine of Sakura Hospital, Toho University for their cooperation in conducting research on CAVI. We sincerely acknowledge the staff of the Functional Physiological Division of Sakura Hospital, Toho University for their high quality technical examinations.

References

- 1) Asmar R: Pulse wave velocity principles and measurement 25-55. In: Arterial stiffness and pulse wave velocity, edited by Asmar R, O'Rourke MF, Safar M. Elsevier, Amsterdam, 1999
- 2) Oliver JJ, Webb DJ: Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol*, 2003; 23: 554-566
- 3) Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Rene-man RS, Hoeks AP, Breteler MM, Witteman JC: Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation*, 2006; 113: 657-663
- 4) O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE: Clinical applications of arterial stiffness; definitions and reference values. *Am J Hypertens*, 2002; 15: 426-444
- 5) Koizumi M, Shimizu H, Shimomura K, Oh-I S, Tomita Y, Kudo T, Iizuka K, Mori M: Relationship between hyperinsulinemia and pulse wave velocity in moderately hyperglycemic patients. *Diabetes Res ClinPr*, 2003; 62: 17-21
- 6) Avest E, Holewijn S, Bredie SJ, van Tits LJ, Stalenhoef AF, de Graaf J: Pulse wave velocity in familial combined hyperlipidemia. *Am J Hypertens*, 2007; 20: 263-269
- 7) Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, Tomiyama H, Yamashina A, Yasuda H, Sawayama T, Ozawa T: Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. *J Hypertens*, 2009; 27: 2022-2027
- 8) Lemogoum D, Flores G, Van den Abeele W, Ciarka A, Leeman M, Degaute JP, van de Borne P, Van Bortel L: Validity of pulse pressure and augmentation index as surrogate measures of arterial stiffness during beta-adrenergic stimulation. *J Hypertens*, 2004; 2: 511-517
- 9) Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K: Stiffness and elastic behavior of human intracranial and extracranial arteries. *J Biomech*, 1980; 13: 175-184
- 10) Kawasaki T, Sasayama S, Yagi S: Noninvasive assessment of the age related changes in stiffness of major branches of the human arteries. *Cardiovascular Res*, 1987; 21: 678-687
- 11) Frank O: Die Theorie der Pulswellen. *Zeitschrift fur Biologie*, 1926; 85: 91-130
- 12) Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Koji Y, Hori S, Yamamoto Y: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res*, 2002; 25: 359-364
- 13) Kim HJ, Nam JS, Park JS, Cho M, Kim CS, Ahn CW, Kwon HM, Hong BK, Yoon YW, Cha BS, Kim KR, Lee HC: Usefulness of brachial-ankle pulse wave velocity as a predictive marker of multiple coronary artery occlusive disease in Korean type 2 diabetes patients. *Diabetes Res Clin Pr*, 2009; 85: 30-34
- 14) Nye ER: The effect of blood pressure alteration on the pulse wave velocity. *Br Heart J*, 1964; 266: 261-265
- 15) Hasegawa M: Fundamental research on human aortic pulse wave velocity. *Jikei Medical Journal*, 1970; 85: 742-760
- 16) Hamazaki T, Urakaze M, Sawazaki S, Yamazaki K, Taki H, Yano S: Comparison of pulse wave velocity of the aorta between inhabitants of fishing and farming villages in Japan. *Atherosclerosis*, 1988; 73: 157-160
- 17) Saito Y, Shirai K, Utino J, Okazaki M, Hattori Y, Yoshida T, Yoshida S: Effect of nefedipine administration on pulse wave velocity of chronic hemodialysis patients- 2 years trial. *Cardiovas Drug Ther*, 1990; 4: 987-990
- 18) Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). *J Atheroscler Thromb*,

- 2006; 13: 101-107
- 19) Bramwell JC, Hill AV: Velocity of the pulse wave in man. *Proc Roy Soc*, 1922; B: 298-306
 - 20) Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Matsuda T, Hiratsuka A, Matsuzaki M: Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. *Circ J*, 2007; 71: 1710-1714
 - 21) Kubozono T, Miyata M, Ueyama K, Nagaki A, Otsuji Y, Kusano K, Kubozono O, Tei C: Clinical significance and reproducibility of new arterial distensibility index. *Circ J*, 2007; 71: 89-94
 - 22) Ibara J, Sasaki H, Kakimoto T, Matsuno S, Nakatani M, Kobayashi M, Tatsumi K, Nakano Y, Wakasaki H, Furuta H, Nishi M, Nanjo K: Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. *Diabetes Res Clin Pr*, 2008; 80: 265-270
 - 23) Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M: Contradictory effects of β 1- and α 1- adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) -the independency of CAVI from blood pressure. *J Atheroscler Thromb*, 2011; 18: 49-55
 - 24) Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H: Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. *Circ J*, 2008; 72: 598-604
 - 25) Izuohara M, Shioji K, Kadota S, Baba O, Takeuchi Y, Uegaito T, Mutsuo S, Matsuda M: Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary atherosclerosis. *Circ J*, 2008; 72: 1762-1767
 - 26) Miyoshi T, Doi M, Hirohata S, Sakane K, Kamikawa S, Kitawaki T, Kaji Y, Kusano KF, Ninomiya Y, Kusachi S: Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. *J Atheroscler Thromb*, 2010; 17: 249-258
 - 27) Horinaka S, Yabe A, Yagi H, Ishimura K, Hara H, Iemua T, Matsuoka H: Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity. *Angiology*, 2009; 60: 468-476
 - 28) Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Hiratsuka A, Matsuzaki M: Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. *Hypertens Res*, 2008; 31: 1347-1355
 - 29) Sairaku A, Eno S, Hondo T, Teragawa H, Nakano Y, Matsuda K, Kisaka T, Kihara Y: Head-to-head comparison of the cardio-ankle vascular index between patients with acute coronary syndrome and stable angina pectoris. *Hypertens Res*, 2010; 33: 1162-1166
 - 30) Kubozono T, Miyata M, Ueyama K, Nagaki A, Hamasaki S, Kusano K, Kubozono O, Tei C: Association between arterial stiffness and estimated glomerular filtration rate in the Japanese general population. *J Atheroscler Thromb*, 2009; 16: 840-845
 - 31) Takenaka T, Hoshi H, Kato N, Kobayashi K, Takane H, Shoda J, Suzuki H: Cardio-ankle vascular index to screen cardiovascular diseases in patients with end-stage renal diseases. *J Atheroscler Thromb*, 2008; 15: 339-344
 - 32) Nakamura K, Iiduka T, Takahashi M, Shimizu S, Mikamo H, Nakagami T, Suzuki M, Hirano K, Sugiyama Y, Tomaru T, Miyashita Y, Shirai K, Noike H: Association between cardio-ankle vascular index and serum cystatin c levels in patients with cardiovascular risk factor. *J Atheroscler Thromb*, 2009; 16: 371379-370
 - 33) Ueyama K, Miyata M, Kubozono T, Nagaki A, Hamasaki S, Ueyama S, Tei C: Noninvasive indices of arterial stiffness in hemodialysis patients. *Hypertens Res*, 2009; 32: 716-720
 - 34) Ichihara A, Yamashita N, Takemitsu T, Kaneshiro Y, Sakoda M, Kurauchi-Mito A, Itoh H: Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis. *Am J Kidney Dis*, 2008; 52: 947-955
 - 35) Shen TW, Wang CH, Lai YH, Hsu BG, Liou HH, Fang TC: Use of cardio-ankle vascular index in chronic dialysis patients. *Eur J Clin Invest*, 2011; 41: 45-51
 - 36) Satoh-Asahara N, Suganami T, Majima T, Kotani K, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Oishi M, Himeno A, Kono, Sugawara A, Hattori M, Ogawa Y, Shimatsu, A and the Japan Obesity and Metabolic Syndrome Study (JOMS) Group: Urinary Cystatin C as a Potential Risk Marker for Cardiovascular Disease and Chronic Kidney Disease in Patients with Obesity and Metabolic Syndrome. *Clin J Am Soc Nephrol*, 2011; 6: 265-273
 - 37) Okura T, Watanabe S, Kurata M, Manabe S, Koresawa M, Irita J, Enomoto D, Miyoshi K, Fukuoka T, Higaki J: Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. *Hypertens Res*, 2007; 30: 335-340
 - 38) Hayashi S: Significance of plasma D-dimer in relation to the severity of atherosclerosis among patients evaluated by non-invasive indices of cardio-ankle vascular index and carotid intima-media thickness. *Int J Hematol*, 2010; 92: 76-82
 - 39) Yamamoto N, Yamanaka G, Ishikawa M, Takasugi E, Murakami S, Yamanaka T, Ishine M, Matsubayashi K, Hanafusa T, Otsuka K: Cardio-ankle vascular index as a predictor of cognitive impairment in community-dwelling elderly people: four-year follow-up. *Dement Geriatr Cogn Disord*, 2009; 28: 153-158
 - 40) Kato A, Takita T, Furuhashi M, Kumagai H, Hishida A: A small reduction in the ankle-brachial index is associated with increased mortality in patients on chronic hemodialysis. *Nephron Clin Pract*, 2010; 114: c29-37
 - 41) Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Matsuda T, Hiratsuka A, Matsuzaki M: Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. *Circ J*, 2007; 71: 1710-1714
 - 42) Kadota K, Takamura N, Aoyagi K, Yamasaki H, Usa T, Nakazato M, Maeda T, Wada M, Nakashima K, Abe K, Takeshima F, Ozono Y: Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. *Circ J*, 2008; 72: 304-308
 - 43) Masugata H, Senda S, Himoto T, Okuyama H, Inukai M, Muraio K, Hosomi N, Yukiiri K, Kohno M, Yamagami A, Kohno T, Goda F: Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle